PT - JOURNAL ARTICLE AU - Rohan Khera AU - Faseeha Altaf AU - Yongfei Wang AU - Susannah M. Bernheim AU - Zhenqiu Lin AU - Sharon-Lise T. Normand AU - Harlan M. Krumholz TI - Isolating Effects of Medicare Code Slot Expansion on Longitudinal Risk Assessment AID - 10.1101/19010074 DP - 2019 Jan 01 TA - medRxiv PG - 19010074 4099 - http://medrxiv.org/content/early/2019/10/29/19010074.short 4100 - http://medrxiv.org/content/early/2019/10/29/19010074.full AB - Background The evaluation of trends in patient outcomes requires adjustment for the changes in case-mix over time and, thus, could be influenced by the expansion of code slots on inpatient claims that occurred in January 2011. We tested the hypothesis that the changes in code slots caused an artifactual increase in the case mix over time compared with a strategy that restricted inpatient codes to the same number of slots over time, excluding consideration of codes beyond the first 9 after the expansion.Methods In Medicare claims over a 5-year period spanning the inpatient code slot expansion (2008-2012), we created cohorts of hospitalizations for heart failure (HF), acute myocardial infarction (AMI) and pneumonia, common hospitalization conditions included in federal policies. We obtained information on risk factors for 30-day post-discharge mortality or readmission for each condition from inpatient facility Medicare claims, outpatient facility claims and professional (or carrier) claims. We evaluated the effects of additional codes captured from the expanded slots in inpatient claims on the number of risk factors or model covariates, overall and based on their contribution to the risk of mortality or readmission. We modelled the effects of code expansion on risk-assessment using an interrupted time series framework.Results There were 2,102,509 eligible hospitalizations for HF, 872,734 for AMI and 1,824,079 for pneumonia. The average number of risk factors increased across all covariate selection strategies. There was a larger increase in monthly average covariate count that included all codes at the time of the code slot increase relative to a strategy that consistently used only 9 inpatient codes (level change in interrupted time series model, 0.9% [95% CI 0.7% to 1.1%] in HF, 0.6% [0.5% to 0.7%] for AMI and 0.6% [0.4% to 0.8%] for pneumonia). Using both inpatient and outpatient/carrier codes for assessing risk factors, there was a smaller difference between strategies using 9 inpatient codes, compared with all inpatient claims (relative excess increase in covariates by 0.6% [0.4% to 0.8%] in HF, 0.4% [0.3% to 0.5%] for AMI, and 0.3% [0.1% to 0.6%] in pneumonia). However, the additional codes were limited to covariates with small contributions to the risk-adjustment models for mortality, without a significant inflection in measured risk of mortality across code expansion (P>0.05 in interrupted time-series models). Measured readmission risk increased with using only inpatient claims for risk assessment, but not if all outpatient and carrier claims were also used (P>0.05 in interrupted time-series models).Conclusions The expansion of inpatient code slots did not meaningfully affect the measurement of the risk of mortality or readmission, especially if comprehensive inpatient and outpatient claims are used, because the additional covariates only included conditions with a modest influence on risk adjusted models. The use of all versus limited codes after the code slot expansion has a minimal effect on evaluating trends in these conditions.Competing Interest StatementDr. Krumholz is a recipient of a research grant, through Yale, from Medtronic and Johnson & Johnson (Janssen) to develop methods of clinical trial data sharing; was a recipient of a research grant, through Yale, from Medtronic and the Food and Drug Administration to develop methods for post-market surveillance of medical devices; was a recipient of a research agreement, through Yale, from the Shenzhen Center for Health Information for work to advance intelligent disease prevention and health promotion, and collaborates with the National Center for Cardiovascular Diseases in Beijing; received payment from the Arnold & Porter Law Firm for work related to the Sanofi clopidogrel litigation and from the Ben C. Martin Law Firm for work related to the Cook IVC filter litigation; chairs a cardiac scientific advisory board for UnitedHealth; is a participant/participant representative of the IBM Watson Health Life Sciences Board; is a member of the Advisory Board for Element Science, the Physician Advisory Board for Aetna, and the Advisory Board for Facebook; and is the founder of Hugo, a personal health information platform. Drs. Krumholz, Bernheim, and Lin, and Mr. Wang work under contract with the Centers for Medicare & Medicaid Services to develop and maintain performance measures that are publicly reported. The other authors report no potential conflicts of interest. The study was conceived and conducted by the authors, and the Centers for Medicare & Medicaid Services played no role in its design and conduct; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. Funding StatementDr. Khera is supported by the National Center for Advancing Translational Sciences (UL1TR001105) of the National Institutes of Health. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesThe data are proprietary of the CMS but can be obtained from them directly under a data use agreement directly with the CMS,